Emerging Biomarkers and Precision Immunology in Modern Clinical Immunology: Current Applications and Future Directions

Abstract

Clinical immunology is undergoing a major transformation from traditional disease-centered approaches toward precision medicine based on a deeper understanding of immune pathogenesis and patient-specific biological characteristics. Conventional biomarkers, including    autoantibodies, complement proteins, and acute-phase reactants, remain essential for diagnosis and disease monitoring.  However, their ability to predict disease progression, explain inter-individual variability, and guide personalized treatment decisions is often limited. Recent advances in omics technologies, including genomics, transcriptomics, proteomics, metabolomics, epigenetics, and single-cell analysis, have significantly improved the understanding of immune-mediated diseases. These technologies enable the identification of molecular signatures, disease mechanisms, and biologically distinct patient subgroups. In parallel, growing research on the human microbiome and the emergence of artificial intelligence (AI) have expanded the analytical capabilities of clinical immunology by integrating molecular, environmental, and clinical data into comprehensive predictive models. This review examines the evolving role of traditional and emerging biomarkers in clinical practice and evaluates how multi-omics platforms, microbiome research, and AI-driven approaches can support personalized therapeutic decision-making in autoimmune diseases.

The synthesis identifies three consistent findings: conventional biomarkers remain indispensable for diagnosis and monitoring but have limited predictive precision; multi-omics and microbiome-derived signatures improve biological stratification but remain largely translational; and AI can integrate these data for risk and treatment-response prediction, although external validation, interpretability, and equitable implementation are still required before routine clinical adoption. Despite substantial progress, significant barriers remain to clinical implementation, including methodological heterogeneity, limited external validation, high costs, complex bioinformatics requirements, ethical concerns, and unequal access to advanced technologies. Precision immunology should therefore be viewed as an evolving clinical paradigm rather than an established standard. The integration of validated molecular biomarkers with clinical expertise offers considerable potential to advance predictive, preventive, and personalized healthcare in immunology.